Skyla (Levonorgestrel) Patent Expiration, LOE Window & CMS Spending
Skyla (Levonorgestrel) by Bayer: FDA Orange Book LOE 2029-09-16, 0 AB generics, $5.3M 2024 CMS Part D & Medicaid spend.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Consolidated Sponsor | Bayer |
| FDA Application & Pathway | N203159 (NDA) |
| Exclusivity / Cliff Horizon | Near-Term Cliff (2028-2030) |
| Core Active-Ingredient LOE Date | Not listed / N/A |
| Last Listed Patent or Exclusivity Date | 2029-09-16 |
| Orange Book Patents (*PED Extensions) | 3 patents (0 *PED) |
| Active AB-Rated Generic Competitors | 0 |
| 2024 CMS Total Public Spend | $5.3M |
| 2024 Medicare Part D Spend | $12K |
| 2024 Medicaid Spend | $5.3M |
| Reported Wholesale Price Change (CA SB 17) | 0 statutory filings in 2023 to 2026 panel |
Related Filings Across Meru Platforms
Verified cross-ledger federal filings for Bayer across sibling Meru public-data platforms.
- Predicate Ledger FDA 510(k)Bayer FDA 510(k) & Recall Cohortdevices.meruai.co →
- Protocol Ledger NIH ClinicalTrials.govBayer Clinical Trials & Approvalstrials.meruai.co →
- ERISA Ledger DOL Form 5500Bayer 401(k) & Form 5500 Planerisa.meruai.co →
- Plume Ledger EPA TRI & RCRABayer U.S. TRI & RCRA Facilitieshazmat.meruai.co →